Where is Genmab A/S (GMAB) Headed According to Wall Street?

Core Insights - Genmab A/S (NASDAQ:GMAB) is recognized as a promising healthcare stock priced under $50, with significant sales figures reported for its product DARZALEX, totaling $14.351 billion in worldwide net trade sales for 2025 [1] - The company has received positive price target adjustments from analysts, with H.C. Wainwright setting a target of $39 and BofA adjusting it to $38.50, both maintaining a Buy rating, indicating confidence in Genmab's future performance [2] Company Overview - Genmab A/S is an international biotechnology company focused on developing human antibody therapeutics for cancer and other diseases, with a product pipeline that includes DARZALEX for multiple myeloma, TEPEZZA for thyroid eye disease, and Arzerra for chronic lymphocytic leukemia [3]